Verteporfin for Recurrent High Grade EGFR-Mutated Glioblastoma
Phase 1/2
24
about 4.6 years
18+
1 site in GA
What this study is about
This trial is testing the safety and effectiveness of verteporfin, a drug called Visudyne, in treating recurrent high grade EGFR-mutated glioblastoma. Verteporfin is being used as a treatment to kill tumor cells that may be sensitive to this medication.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Verteporfin
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
verteporfin
injection, intravenous
Primary: Incidence of adverse events (Phase I), Overall survival (Phase II), Progression free survival (PFS) (Phase II), Response rate (RR) (Phase II)
Secondary: Incidence of adverse events (Phase II), Overall survival (Phase I), PFS (Phase I)
Oncology